Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2
Targeted drug conjugates based on Affibody molecules fused to an albumin-binding domain (ABD) for half-life extension have demonstrated potent anti-tumor activity in preclinical therapeutic studies. Furthermore, optimization of their molecular design might increase the cytotoxic effect on tumors and...
Saved in:
Main Authors: | Tianqi Xu (Author), Jie Zhang (Author), Maryam Oroujeni (Author), Maria S. Tretyakova (Author), Vitalina Bodenko (Author), Mikhail V. Belousov (Author), Anna Orlova (Author), Vladimir Tolmachev (Author), Anzhelika Vorobyeva (Author), Torbjörn Gräslund (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution
by: Haozhong Ding, et al.
Published: (2021) -
The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy
by: Wen Yin, et al.
Published: (2021) -
Preclinical Evaluation of a New Format of <sup>68</sup>Ga- and <sup>111</sup>In-Labeled Affibody Molecule Z<sub>IGF-1R:4551</sub> for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT
by: Yongsheng Liu, et al.
Published: (2022) -
Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody<sup>®</sup> Molecules <sup>177</sup>Lu-ABY-271 and <sup>177</sup>Lu-ABY-027: Impact of DOTA Position on ABD Domain
by: Yongsheng Liu, et al.
Published: (2021) -
Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart
by: Javad Garousi, et al.
Published: (2022)